A study on the effects of culture supernatant of human somatic stem cells on liver cirrhosis

A study on the effects of culture supernatant of human somatic stem cells on liver cirrhosis - The effects of culture supernatant of human stem cells on liver cirrhosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014211

Enrollment

Registered

2014-06-10

Start date

2014-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Intravenous administration of 10ml of culture supernatant of human somatic stem cells once a week, 4 times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients with liver cirrhosis under treatment. -Treatment has not been changed within the previous one month, and it is anticipated that the treatment will not be changed within the next one month. -Patients with T-bil < 5mg/dl and serum Alb <= 3.5g/dl.

Exclusion criteria

Exclusion criteria: -Patients with malignant diseases -patients with hepatic coma -Patients with serum Cr >= 2mg/dl -Patients with HIV infection -Patients with autoimmune diseases -Patients who had bleeding from esophageal or gastric varices within the previous 3 months -Patients with severe organ dysfunction -Patients infected with unknown microbe

Design outcomes

Primary

Measure	Time frame
Safety; Evaluation of adverse events of clinical symptoms and data	—

Secondary

Measure	Time frame
Efficacy; Subjective symptoms; general fatigue, itching, abdominal fullness, cramp in the legs Objective signs; hepatic coma, ascites, edema, bleeding tendency Laboratory data; AST, ALT, T-Bil, PT, Plt, Alb, P-III-P, Type IV collagen 7S, hyaluronic acid	—

Countries

Japan

Contacts

Public ContactKazumasa Hiroishi, MD

Shin-yurigaoka General Hospital Department of Gastroenterology

kazumasa.hiroishi@mt.strins.or.jp044-322-9991

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026